EHMT1 Antikörper

Produktnummer ABIN966204

Zitiert in 2+ Publikationen. Der Monoklonal anti-EHMT1 Antikörper (ABIN966204) detektiert spezifisch EHMT1 in WB und ELISA. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für EHMT1 Antikörper (ABIN966204)

Target: EHMT1 (Euchromatic Histone-Lysine N-Methyltransferase 1 (EHMT1))

Reaktivität: Human

Wirt: Bitte anfragen

Klonalität: Monoklonal

Konjugat: Dieser EHMT1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Produktdetails anti-EHMT1 Antikörper

Spezifität: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)

Aufreinigung: Antibodies are purified by protein A affinity chromatography

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Western Blot: Dilution 1: 200- 1: 1,000
ELISA: Propose dilution 1: 10,000
Determining optimal working dilutions by titration test.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: -20 °C

Referenzen für anti-EHMT1 Antikörper (ABIN966204)

Young: "Inhibition of glucagon secretion." in: Advances in pharmacology (San Diego, Calif.), Vol. 52, pp. 151-71, (2006) (PubMed).

De León, Crutchlow, Ham, Stoffers: "Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus." in: The international journal of biochemistry & cell biology, Vol. 38, Issue 5-6, pp. 845-59, (2006) (PubMed).

Details zu EHMT1

Target: EHMT1 (Euchromatic Histone-Lysine N-Methyltransferase 1 (EHMT1))

Andere Bezeichnung: GLP

Hintergrund: Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine L cells in response to ingested nutrients. The closely related peptides glucagon-like peptide (GLP-1) and glucagon have opposing effects on blood glucose. GLP-1 induces glucose-dependent insulin secretion in the pancreas, while glucagon stimulates gluconeogenesis and glycogenolysis in the liver. Glucagon is processed from a large precursor, proglucagon, in a tissue-specific manner in pancreatic alpha-cells. The identification of a hybrid peptide acting as both a GLP-1 agonist and a glucagon antagonist would provide a novel approach for the treatment of type 2 diabetes.

Gen-ID: 79813